Follow-Up Visits for Premature Infants
(FU Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand the early development of infants born extremely small and early. Researchers seek to identify factors during pregnancy and shortly after birth that might influence the growth and development of these infants, particularly regarding brain and sensory functions. The study involves no treatments; it focuses solely on gathering information. It suits infants born at specific hospitals before 27 weeks of pregnancy who are already participating in related studies. As an unphased study, this trial provides families with a unique opportunity to contribute to vital research that could enhance future care for extremely premature infants.
Do I need to stop my current medications for the trial?
The trial information does not specify whether participants need to stop taking their current medications.
Why are researchers excited about this trial?
Researchers are excited about the "Follow-up Visit of High Risk Infants" trial because it aims to gather crucial long-term data on infants considered at high risk, something that current treatment options do not typically address. Unlike traditional approaches that focus on immediate treatment, this trial emphasizes understanding the developmental trajectory and health outcomes of these infants over time. By collecting detailed information through a registry cohort, researchers hope to uncover patterns and insights that could lead to improved care strategies and early interventions, potentially transforming how we support high-risk infants in the future.
Who Is on the Research Team?
Edward F. Bell, MD
Principal Investigator
University of Iowa
Brenda B. Poindexter, MD
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Waldemar A. Carlo, MD
Principal Investigator
University of Alabama at Birmingham
Pablo J. Sanchez, MD
Principal Investigator
Research Institute at Nationwide Children's Hospital
Abhik Das, PhD
Principal Investigator
RTI International
Uday Devaskar, MD
Principal Investigator
University of California, Los Angeles
Eric C Eichenwald, MD
Principal Investigator
University of Pennsylvania
Kristi L. Watterberg, MD
Principal Investigator
University of New Mexico
Greg M. Sokol, MD
Principal Investigator
Indiana University
Michele C. Walsh, MD MS
Principal Investigator
Case Western Reserve University, Rainbow Babies and Children's Hospital
Carl T D'Angio, MD
Principal Investigator
University of Rochester
David P. Carlton, MD
Principal Investigator
Emory University
Abbot R. Laptook, MD
Principal Investigator
Brown University, Women & Infants Hospital of Rhode Island
C. Michael Cotten, MD, MHS
Principal Investigator
Duke University
Myra H. Wyckoff, MD
Principal Investigator
University of Texas, Southwestern Medical Center at Dallas
Jon E Tyson, MD, MPH
Principal Investigator
The University of Texas Health Science Center, Houston
Bradley A. Yoder, MD
Principal Investigator
University of Utah
Seetha Shankaran, MD
Principal Investigator
Wayne State University
Krisa P. Van Meurs, MD
Principal Investigator
Stanford University
William E. Truog, MD
Principal Investigator
Children's Mercy Hospital Kansas City
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Neurodevelopmental, neurosensory, and functional assessments at 22-26 months corrected age
Follow-up
Participants are monitored for neurodevelopmental outcomes and potential risk factors
What Are the Treatments Tested in This Trial?
Interventions
- None
Find a Clinic Near You
Who Is Running the Clinical Trial?
NICHD Neonatal Research Network
Lead Sponsor
National Center for Research Resources (NCRR)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator